Obesity and High-density lipoprotein Cholesterol (HDL-C) : The Recent Related Research Trend Including New Generation Drugs for HDL-C

Low levels of high-density lipoprotein cholesterol (HDL-C) are associated with the development of cardiovascular disease (CVD). In addition, under the state of obesity, HDL particles can be modified to generate dysfunctional HDL-C which is a more important risk factor for CVD. Despite strong evidence of the protective effect of HDL-C to CVD, there are no potent HDL elevators available. However, new insights in HDL biology have recently allowed the development of promising actions aimed to enhance HDL function and promote atherogenesis regression in obesity. Growing burdens of HDL-C action and new generation agents which are thought to be able to raise HDL-C or enhance its function are discussed in this review.